Suppr超能文献

基于结构的 SD-36 发现:一种强效、选择性且有效的 STAT3 蛋白 PROTAC 降解剂。

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein.

出版信息

J Med Chem. 2019 Dec 26;62(24):11280-11300. doi: 10.1021/acs.jmedchem.9b01530. Epub 2019 Dec 10.

Abstract

Signal transducer and activator of transcription 3 (STAT3) is a transcription factor and an attractive therapeutic target for cancer and other human diseases. Despite 20 years of persistent research efforts, targeting STAT3 has been very challenging. We report herein the structure-based discovery of potent small-molecule STAT3 degraders based upon the proteolysis targeting chimera (PROTAC) concept. We first designed SI-109 as a potent, small-molecule inhibitor of the STAT3 SH2 domain. Employing ligands for cereblon/cullin 4A E3 ligase and SI-109, we obtained a series of potent PROTAC STAT3 degraders, exemplified by SD-36. SD-36 induces rapid STAT3 degradation at low nanomolar concentrations in cells and fails to degrade other STAT proteins. SD-36 achieves nanomolar cell growth inhibitory activity in leukemia and lymphoma cell lines with high levels of phosphorylated STAT3. A single dose of SD-36 results in complete STAT3 protein degradation in xenograft tumor tissue and normal mouse tissues. SD-36 achieves complete and long-lasting tumor regression in the Molm-16 xenograft tumor model at well-tolerated dose-schedules. SD-36 is a potent, selective, and efficacious STAT3 degrader.

摘要

信号转导子和转录激活因子 3(STAT3)是一种转录因子,是癌症和其他人类疾病的有吸引力的治疗靶点。尽管经过 20 年的持续研究努力,靶向 STAT3 一直极具挑战性。我们在此报告了基于蛋白水解靶向嵌合体(PROTAC)概念的强效小分子 STAT3 降解剂的基于结构的发现。我们首先设计了 SI-109,作为 STAT3 SH2 结构域的有效小分子抑制剂。我们使用 cereblon/cullin 4A E3 连接酶配体和 SI-109,得到了一系列强效的 PROTAC STAT3 降解剂,以 SD-36 为例。SD-36 在细胞中以低纳摩尔浓度快速诱导 STAT3 降解,并且不会降解其他 STAT 蛋白。SD-36 在具有高磷酸化 STAT3 水平的白血病和淋巴瘤细胞系中实现了纳摩尔级的细胞生长抑制活性。单次给予 SD-36 可导致异种移植肿瘤组织和正常小鼠组织中 STAT3 蛋白完全降解。SD-36 在可耐受剂量方案下,在 Molm-16 异种移植肿瘤模型中实现了完全和持久的肿瘤消退。SD-36 是一种有效、选择性和有效的 STAT3 降解剂。

相似文献

引用本文的文献

3
Advancing Design Strategy of PROTACs for Cancer Therapy.用于癌症治疗的PROTACs的先进设计策略
MedComm (2020). 2025 Jun 25;6(7):e70258. doi: 10.1002/mco2.70258. eCollection 2025 Jul.
9
The Peptide PROTAC Modality: A New Strategy for Drug Discovery.肽类PROTAC技术:药物发现的新策略。
MedComm (2020). 2025 Mar 24;6(4):e70133. doi: 10.1002/mco2.70133. eCollection 2025 Apr.

本文引用的文献

2
Targeted protein degradation: elements of PROTAC design.靶向蛋白降解:PROTAC 设计要素。
Curr Opin Chem Biol. 2019 Jun;50:111-119. doi: 10.1016/j.cbpa.2019.02.022. Epub 2019 Apr 17.
8
Targeting the IL-6/JAK/STAT3 signalling axis in cancer.针对癌症中的 IL-6/JAK/STAT3 信号通路。
Nat Rev Clin Oncol. 2018 Apr;15(4):234-248. doi: 10.1038/nrclinonc.2018.8. Epub 2018 Feb 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验